Evidence map›Paper›PMID 40208053›Full record

ReviewTechnology in cancer research & treatment

The Gut Microbiome and Its Multifaceted Role in Cancer Metabolism, Initiation, and Progression: Insights and Therapeutic Implications.

Kai Xu, Zainab Motiwala, Irene Corona-Avila, Dhruvi Makhanasa, Leen Alkahalifeh, Md Wasim Khan

Abstract readReview
In one paragraph

Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Microbiome-guided cancer immunotherapy: immune mechanisms, resistance pathways, and translational opportunities for precision oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kai XuDivision of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, IL, USA.
Zainab MotiwalaJawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India.ORCID 0000-0002-9659-6181
Irene Corona-AvilaDivision of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, IL, USA.
Dhruvi MakhanasaDivision of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, IL, USA.
Leen AlkahalifehAl Mouwassat University Hospital, Damascus, Syria.
Md Wasim KhanDivision of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, IL, USA.ORCID 0000-0002-4398-8798

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review summarizes the intricate relationship between the microbiome and cancer initiation and development. Microbiome alterations impact metabolic pathways, immune responses, and gene expression, which can accelerate or mitigate cancer progression. We examine how dysbiosis affects tumor growth, metastasis, and treatment resistance. Additionally, we discuss the potential of microbiome-targeted therapies, such as probiotics and fecal microbiota transplants, to modulate cancer metabolism. These interventions offer the possibility of reversing or controlling cancer progression, enhancing the efficacy of traditional treatments like chemotherapy and immunotherapy. Despite promising developments, challenges remain in identifying key microbial species and pathways and validating microbiome-targeted therapies through large-scale clinical trials. Nonetheless, the intersection of microbiome research and cancer initiation and development presents an exciting frontier for innovative therapies. This review offers a fresh perspective on cancer initiation and development by integrating microbiome insights, highlighting the potential for interdisciplinary research to enhance our understanding of cancer progression and treatment strategies.

Indexed as

Gastrointestinal MicrobiomeNeoplasmsAnimalsDisease ProgressionDysbiosisFecal Microbiota TransplantationHumansProbioticsbiomarkercancergut microbiomemechanismtherapy

Identifiers

PMID40208053
PMCPMC12032467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.